Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abatacept plus methotrexate versus placebo plus methotrexate in early erosive rheumatoid arthritis
ACTRN12605000784617Phase 3Recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Jan 2006
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in rheumatoid arthritis (RA) comparing Abatacept plus methotrexate with Placebo plus methotrexate then abatacept plus methotrexate (2 arms). Primary endpoints: Remission by DAS28 and Radiographic joint damage progression. Started Jan 2006; status: recruiting.
02
Drugs
abataceptmethotrexate
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on ACTRN12605000784617.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12605000784617.